Global Health Policy
« Demand Forecasting Featured in Scientific American | Main | Health Affairs on Cardiovascular Disease »
January 11, 2007
Outwitting & Outwaiting ARV Resistance
Posted by Jessica Pickett at 03:56 PM
In the best health news of the year (so far!), a new New England Journal of Medicine study has found that delaying the start of a nevirapine-based antiretroviral therapy by six months can prevent the development of drug resistance in HIV-positive women who took single-dose nevirapine during labor to prevent mother-to-child transmission of the virus. (See the Harvard and NIH press releases and coverage in the NY Times and Boston Globe for more details.) This exciting finding makes for a nice complement to the malaria ACT subsidy proposal and research on the re-emerging effectiveness of chloroquine as part of a new resistance dialogue focusing on policy recommendations to make existing drugs last longer and not just blindly relying on our ability to develop new ones.
Trackback Ping
TrackBack URL for this entry:
/mt/mt-tb.cgi/744